{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:04:11Z","timestamp":1793138651657,"version":"4.5.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11030-025-11237-z","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T10:49:04Z","timestamp":1749811744000},"page":"1051-1070","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Quinazolinone based broad-spectrum antiviral molecules: design, synthesis, in silico studies and biological evaluation"],"prefix":"10.1007","volume":"30","author":[{"given":"Abdallah E.","family":"Abdallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omkulthom","family":"Al kamaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmail M.","family":"El-Fakharany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousra A.","family":"El-Maradny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelaaty A.","family":"Shahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Alesawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ayman","family":"El-Zahabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiha A.","family":"El-Sebaey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona S.","family":"El-Zoghbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"issue":"5","key":"11237_CR1","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3390\/ijerph17051633","volume":"17","author":"Z Sun","year":"2020","unstructured":"Sun Z et al (2020) Potential factors influencing repeated SARS outbreaks in China. Int J Environ Res Public Health 17(5):1633","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"11237_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.diagmicrobio.2018.10.011","volume":"93","author":"A Al-Omari","year":"2019","unstructured":"Al-Omari A et al (2019) MERS coronavirus outbreak: implications for emerging viral infections. Diagn Microbiol Infect Dis 93(3):265\u2013285","journal-title":"Diagn Microbiol Infect Dis"},{"key":"11237_CR3","doi-asserted-by":"publisher","first-page":"102434","DOI":"10.1016\/j.jaut.2020.102434","volume":"109","author":"Y Yang","year":"2020","unstructured":"Yang Y et al (2020) The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun 109:102434","journal-title":"J Autoimmun"},{"issue":"1","key":"11237_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/oxfordjournals.epirev.a017917","volume":"18","author":"WP Glezen","year":"1996","unstructured":"Glezen WP (1996) Emerging infections: pandemic influenza. Epidemiol Rev 18(1):64\u201376","journal-title":"Epidemiol Rev"},{"issue":"17","key":"11237_CR5","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1001\/jama.2009.1583","volume":"302","author":"JK Louie","year":"2009","unstructured":"Louie JK et al (2009) Factors associated with death or hospitalization due to pandemic 2009 influenza A (H1N1) infection in California. JAMA 302(17):1896\u20131902","journal-title":"JAMA"},{"issue":"10334","key":"11237_CR6","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(21)02796-3","volume":"399","author":"H Wang","year":"2022","unstructured":"Wang H et al (2022) Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020\u201321. The Lancet 399(10334):1513\u20131536","journal-title":"The Lancet"},{"issue":"7","key":"11237_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/14787210.2019.1635009","volume":"17","author":"A Adalja","year":"2019","unstructured":"Adalja A, Inglesby T (2019) Broad-spectrum antiviral agents: a crucial pandemic tool. Expert Rev Anti Infect Ther 17(7):467\u2013470","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"2","key":"11237_CR8","doi-asserted-by":"publisher","first-page":"2002484","DOI":"10.1002\/advs.202002484","volume":"8","author":"Z Zong","year":"2021","unstructured":"Zong Z et al (2021) The functional deubiquitinating enzymes in control of innate antiviral immunity. Adva Sci 8(2):2002484","journal-title":"Adva Sci"},{"key":"11237_CR9","doi-asserted-by":"publisher","first-page":"839624","DOI":"10.3389\/fmicb.2022.839624","volume":"13","author":"Q Zhang","year":"2022","unstructured":"Zhang Q et al (2022) The role of deubiquitinases in virus replication and host innate immune response. Front Microbiol 13:839624","journal-title":"Front Microbiol"},{"issue":"36","key":"11237_CR10","doi-asserted-by":"publisher","first-page":"16557","DOI":"10.1039\/D1NJ02710G","volume":"45","author":"AE Abdallah","year":"2021","unstructured":"Abdallah AE et al (2021) Design and synthesis of new 4-(2-nitrophenoxy) benzamide derivatives as potential antiviral agents: molecular modeling and in vitro antiviral screening. New J Chem 45(36):16557\u201316571","journal-title":"New J Chem"},{"issue":"4","key":"11237_CR11","doi-asserted-by":"publisher","first-page":"e94491","DOI":"10.1371\/journal.pone.0094491","volume":"9","author":"MJ Gonzalez-Hernandez","year":"2014","unstructured":"Gonzalez-Hernandez MJ et al (2014) Chemical derivatives of a small molecule deubiquitinase inhibitor have antiviral activity against several RNA viruses. PLoS ONE 9(4):e94491","journal-title":"PLoS ONE"},{"issue":"10","key":"11237_CR12","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1517\/13543776.2015.1056737","volume":"25","author":"P Farshi","year":"2015","unstructured":"Farshi P et al (2015) Deubiquitinases (DUBs) and DUB inhibitors: a patent review. Expert Opin Ther Pat 25(10):1191\u20131208","journal-title":"Expert Opin Ther Pat"},{"issue":"42","key":"11237_CR13","doi-asserted-by":"publisher","first-page":"16119","DOI":"10.1073\/pnas.0805240105","volume":"105","author":"K Ratia","year":"2008","unstructured":"Ratia K et al (2008) A noncovalent class of papain-like protease\/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci USA 105(42):16119\u201316124","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"11237_CR14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3390\/v15020481","volume":"15","author":"LS L\u00f3pez","year":"2023","unstructured":"L\u00f3pez LS, Calvo EP, Castellanos JE (2023) Deubiquitinating enzyme inhibitors block Chikungunya virus replication. Viruses 15(2):481","journal-title":"Viruses"},{"issue":"24","key":"11237_CR15","doi-asserted-by":"publisher","first-page":"15199","DOI":"10.1128\/JVI.79.24.15199-15208.2005","volume":"79","author":"HA Lindner","year":"2005","unstructured":"Lindner HA et al (2005) The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J Virol 79(24):15199\u201315208","journal-title":"J Virol"},{"issue":"24","key":"11237_CR16","doi-asserted-by":"publisher","first-page":"15189","DOI":"10.1128\/JVI.79.24.15189-15198.2005","volume":"79","author":"N Barretto","year":"2005","unstructured":"Barretto N et al (2005) The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J Virol 79(24):15189\u201315198","journal-title":"J Virol"},{"issue":"21","key":"11237_CR17","doi-asserted-by":"publisher","first-page":"6593","DOI":"10.3390\/molecules26216593","volume":"26","author":"MS Alesawy","year":"2021","unstructured":"Alesawy MS et al (2021) In silico screening of semi-synthesized compounds as potential inhibitors for SARS-CoV-2 papain-like protease: pharmacophoric features, molecular docking, ADMET, toxicity and DFT studies. Molecules 26(21):6593","journal-title":"Molecules"},{"issue":"3","key":"11237_CR18","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/prot.20802","volume":"62","author":"T Sulea","year":"2006","unstructured":"Sulea T et al (2006) Binding site-based classification of coronaviral papain-like proteases. Proteins 62(3):760\u2013775","journal-title":"Proteins"},{"issue":"6","key":"11237_CR19","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1134\/S0006350922060082","volume":"67","author":"P Ershov","year":"2022","unstructured":"Ershov P et al (2022) SARS-COV-2 coronavirus papain-like protease PLpro as an antiviral target for inhibitors of active site and protein-protein interactions. Biophysics 67(6):902\u2013912","journal-title":"Biophysics"},{"issue":"4","key":"11237_CR20","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3390\/v13040667","volume":"13","author":"RJ Geraghty","year":"2021","unstructured":"Geraghty RJ, Aliota MT, Bonnac LF (2021) Broad-spectrum antiviral strategies and nucleoside analogues. Viruses 13(4):667","journal-title":"Viruses"},{"issue":"10","key":"11237_CR21","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.drudis.2021.05.008","volume":"26","author":"ZA Shyr","year":"2021","unstructured":"Shyr ZA et al (2021) Drug combination therapy for emerging viral diseases. Drug Discov Today 26(10):2367\u20132376","journal-title":"Drug Discov Today"},{"issue":"6","key":"11237_CR22","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1021\/jm401712t","volume":"57","author":"YM B\u00e1ez-Santos","year":"2014","unstructured":"B\u00e1ez-Santos YM et al (2014) X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases. J Med Chem 57(6):2393\u20132412","journal-title":"J Med Chem"},{"issue":"7","key":"11237_CR23","doi-asserted-by":"publisher","first-page":"e1002783","DOI":"10.1371\/journal.ppat.1002783","volume":"8","author":"JW Perry","year":"2012","unstructured":"Perry JW et al (2012) Antiviral activity of a small molecule deubiquitinase inhibitor occurs via induction of the unfolded protein response. PLoS Pathog 8(7):e1002783","journal-title":"PLoS Pathog"},{"key":"11237_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ejmech.2012.04.010","volume":"53","author":"Z Wang","year":"2012","unstructured":"Wang Z et al (2012) Design, synthesis and antiviral activity of novel quinazolinones. Eur J Med Chem 53:275\u2013282","journal-title":"Eur J Med Chem"},{"key":"11237_CR25","doi-asserted-by":"publisher","first-page":"112706","DOI":"10.1016\/j.ejmech.2020.112706","volume":"206","author":"G Zhang","year":"2020","unstructured":"Zhang G et al (2020) Design, synthesis and in vitro anti-influenza A virus evaluation of novel quinazoline derivatives containing S-acetamide and NH-acetamide moieties at C-4. Eur J Med Chem 206:112706","journal-title":"Eur J Med Chem"},{"key":"11237_CR26","doi-asserted-by":"publisher","first-page":"105518","DOI":"10.1016\/j.antiviral.2022.105518","volume":"209","author":"IE G\u0142owacka","year":"2023","unstructured":"G\u0142owacka IE et al (2023) Design and synthesis of a new series of hybrids of functionalised N1-[(1H\u20131, 2, 3-triazol-4-yl) methyl] quinazoline-2, 4-dione with antiviral activity against respiratory syncytial virus. Antivir Res 209:105518","journal-title":"Antivir Res"},{"issue":"19","key":"11237_CR27","doi-asserted-by":"publisher","first-page":"13237","DOI":"10.1039\/D4RA02029D","volume":"14","author":"SS El-Hddad","year":"2024","unstructured":"El-Hddad SS et al (2024) Quinazolines and thiazolidine-2, 4-dions as SARS-CoV-2 inhibitors: repurposing, in silico molecular docking and dynamics simulation. RSC Adv 14(19):13237\u201313250","journal-title":"RSC Adv"},{"key":"11237_CR28","doi-asserted-by":"publisher","first-page":"139082","DOI":"10.1016\/j.molstruc.2024.139082","volume":"1317","author":"AE Abdallah","year":"2024","unstructured":"Abdallah AE et al (2024) Immunomodulation and anticancer evaluation of quinazoline-based thalidomide analogs: design, synthesis, docking, and dynamic simulation. J Mol Struct 1317:139082","journal-title":"J Mol Struct"},{"key":"11237_CR29","doi-asserted-by":"publisher","first-page":"135164","DOI":"10.1016\/j.molstruc.2023.135164","volume":"1281","author":"AE Abdallah","year":"2023","unstructured":"Abdallah AE et al (2023) Immunomodulatory quinazoline-based thalidomide analogs: design, synthesis, apoptosis and anticancer evaluations. J Mol Struct 1281:135164","journal-title":"J Mol Struct"},{"issue":"16","key":"11237_CR30","doi-asserted-by":"publisher","first-page":"10488","DOI":"10.1039\/D3RA00066D","volume":"13","author":"AR Kotb","year":"2023","unstructured":"Kotb AR et al (2023) Design, synthesis, anticancer evaluation, and in silico ADMET analysis of novel thalidomide analogs as promising immunomodulatory agents. RSC Adv 13(16):10488\u201310502","journal-title":"RSC Adv"},{"issue":"52","key":"11237_CR31","doi-asserted-by":"publisher","first-page":"33525","DOI":"10.1039\/D2RA06188K","volume":"12","author":"AR Kotb","year":"2022","unstructured":"Kotb AR et al (2022) Design, synthesis, and biological evaluation of novel bioactive thalidomide analogs as anticancer immunomodulatory agents. RSC Adv 12(52):33525\u201333539","journal-title":"RSC Adv"},{"issue":"15","key":"11237_CR32","doi-asserted-by":"publisher","first-page":"12416","DOI":"10.3390\/ijms241512416","volume":"24","author":"RR Mabrouk","year":"2023","unstructured":"Mabrouk RR et al (2023) Design, synthesis, and biological evaluation of new potential unusual modified anticancer immunomodulators for possible non-teratogenic quinazoline-based thalidomide analogs. Int J Mol Sci 24(15):12416","journal-title":"Int J Mol Sci"},{"issue":"15","key":"11237_CR33","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.2174\/1389450117666151209115431","volume":"17","author":"A Mandal","year":"2016","unstructured":"Mandal A et al (2016) Design of lipophilic prodrugs to improve drug delivery and efficacy. Curr Drug Targets 17(15):1773\u20131798","journal-title":"Curr Drug Targets"},{"key":"11237_CR34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.colsurfb.2017.01.032","volume":"152","author":"MT Augusto","year":"2017","unstructured":"Augusto MT et al (2017) Lipophilicity is a key factor to increase the antiviral activity of HIV neutralizing antibodies. Colloids Surf B 152:311\u2013316","journal-title":"Colloids Surf B"},{"key":"11237_CR35","doi-asserted-by":"publisher","first-page":"104695","DOI":"10.1016\/j.bioorg.2021.104695","volume":"109","author":"AE Abdallah","year":"2021","unstructured":"Abdallah AE et al (2021) Design, synthesis and molecular modeling of new quinazolin-4 (3H)-one based VEGFR-2 kinase inhibitors for potential anticancer evaluation. Bioorg Chem 109:104695","journal-title":"Bioorg Chem"},{"issue":"7","key":"11237_CR36","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.3390\/v14071404","volume":"14","author":"M Gro\u00dfe","year":"2022","unstructured":"Gro\u00dfe M et al (2022) Inhibitors of deubiquitinating enzymes interfere with the SARS-CoV-2 papain-like protease and block virus replication in vitro. Viruses 14(7):1404","journal-title":"Viruses"},{"issue":"5","key":"11237_CR37","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.drudis.2019.03.015","volume":"24","author":"LL Ferreira","year":"2019","unstructured":"Ferreira LL, Andricopulo AD (2019) ADMET modeling approaches in drug discovery. Drug Discov Today 24(5):1157\u20131165","journal-title":"Drug Discov Today"},{"issue":"12","key":"11237_CR38","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1021\/jm020017n","volume":"45","author":"DF Veber","year":"2002","unstructured":"Veber DF et al (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45(12):2615\u20132623","journal-title":"J Med Chem"},{"issue":"1\u20133","key":"11237_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","volume":"23","author":"CA Lipinski","year":"1997","unstructured":"Lipinski CA et al (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23(1\u20133):3\u201325","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"11237_CR40","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nrd1032","volume":"2","author":"H Van De Waterbeemd","year":"2003","unstructured":"Van De Waterbeemd H, Gifford E (2003) ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov 2(3):192\u2013204","journal-title":"Nat Rev Drug Discov"},{"key":"11237_CR41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.arabjc.2015.08.003","volume":"11","author":"H Patel","year":"2015","unstructured":"Patel H et al (2015) In search of selective 11\u03b2-HSD type 1 inhibitors without nephrotoxicity: an approach to resolve the metabolic syndrome by virtual based screening. Arab J Chem 11:221\u2013232","journal-title":"Arab J Chem"},{"key":"11237_CR42","volume-title":"Pharmacokinetics and metabolism in drug design","author":"R Mannhold","year":"2012","unstructured":"Mannhold R, Kubinyi H, Folkers G (2012) Pharmacokinetics and metabolism in drug design, vol 51. John Wiley & Sons, New York"},{"issue":"4\u20135","key":"11237_CR43","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0928-0987(02)00219-1","volume":"17","author":"G Klopman","year":"2002","unstructured":"Klopman G, Stefan LR, Saiakhov RD (2002) ADME evaluation: 2. A computer model for the prediction of intestinal absorption in humans. Eur J Pharm Sci 17(4\u20135):253\u2013263","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"11237_CR44","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/j.1747-0285.2009.00791.x","volume":"73","author":"PP Roy","year":"2009","unstructured":"Roy PP, Roy K (2009) QSAR studies of CYP2D6 inhibitor aryloxypropanolamines using 2D and 3D descriptors. Chem Biol Drug Des 73(4):442\u2013455","journal-title":"Chem Biol Drug Des"},{"issue":"1","key":"11237_CR45","first-page":"21","volume":"3","author":"T Ghafourian","year":"2013","unstructured":"Ghafourian T, Amin Z (2013) QSAR models for the prediction of plasma protein binding. BioImpacts 3(1):21","journal-title":"BioImpacts"},{"issue":"18","key":"11237_CR46","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1021\/jm0303195","volume":"47","author":"X Xia","year":"2004","unstructured":"Xia X et al (2004) Classification of kinase inhibitors using a Bayesian model. J Med Chem 47(18):4463\u20134470","journal-title":"J Med Chem"},{"key":"11237_CR47","unstructured":"BIOVIA. QSAR, ADMET and predictive toxicology. https:\/\/www.3dsbiovia.com\/products\/collaborative-science\/biovia-discovery-studio\/qsar-admet-and-predictive-toxicology.html. Accessed May 2020"},{"issue":"4","key":"11237_CR48","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1539-6924.1992.tb00709.x","volume":"12","author":"G Goodrnan","year":"1992","unstructured":"Goodrnan G, Wilson R (1992) Comparison of the dependence of the TD50 on maximum tolerated dose for mutagens and nonmutagens. Risk Anal 12(4):525\u2013533","journal-title":"Risk Anal"},{"key":"11237_CR49","first-page":"111","volume-title":"Issues in risk assessment","author":"National Research Council","year":"1993","unstructured":"National Research Council (1993) Correlation between carcinogenic potency and the maximum tolerated dose: implications for risk assessment. Issues in risk assessment. National Academies Press (US), Washington, DC, pp 111\u2013172"},{"issue":"1","key":"11237_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1062936X.2014.977819","volume":"26","author":"R Gonella Diaza","year":"2015","unstructured":"Gonella Diaza R et al (2015) Comparison of in silico tools for evaluating rat oral acute toxicity. SAR QSAR Environ Res 26(1):1\u201327","journal-title":"SAR QSAR Environ Res"},{"key":"11237_CR51","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/978-1-4939-3609-0_9","volume-title":"In silico methods for predicting drug toxicity","author":"F Pizzo","year":"2016","unstructured":"Pizzo F, Benfenati E (2016) In silico models for repeated-dose toxicity (RDT): prediction of the no observed adverse effect level (NOAEL) and lowest observed adverse effect level (LOAEL) for drugs. In: Benfenati E (ed) In silico methods for predicting drug toxicity. Springer, Cham, pp 163\u2013176"},{"issue":"5","key":"11237_CR52","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1021\/ci049903s","volume":"44","author":"R Venkatapathy","year":"2004","unstructured":"Venkatapathy R, Moudgal CJ, Bruce RM (2004) Assessment of the oral rat chronic lowest observed adverse effect level model in TOPKAT, a QSAR software package for toxicity prediction. J Chem Inf Comput Sci 44(5):1623\u20131629","journal-title":"J Chem Inf Comput Sci"},{"issue":"6","key":"11237_CR53","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0039-6257(01)00211-9","volume":"45","author":"KR Wilhelmus","year":"2001","unstructured":"Wilhelmus KR (2001) The Draize eye test. Surv Ophthalmol 45(6):493\u2013515","journal-title":"Surv Ophthalmol"},{"key":"11237_CR54","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ijbiomac.2020.06.046","volume":"161","author":"EM El-Fakharany","year":"2020","unstructured":"El-Fakharany EM et al (2020) Biochemical characterization and application of a novel lectin from the cyanobacterium Lyngabya confervoides MK012409 as an antiviral and anticancer agent. Int J Biol Macromol 161:417\u2013430","journal-title":"Int J Biol Macromol"},{"key":"11237_CR55","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ijbiomac.2022.04.120","volume":"210","author":"MH Saad","year":"2022","unstructured":"Saad MH et al (2022) Nostoc muscorum is a novel source of microalgal lectins with potent antiviral activity against herpes simplex type-1. Int J Biol Macromol 210:415\u2013429","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"11237_CR56","doi-asserted-by":"publisher","first-page":"15921","DOI":"10.1038\/s41598-023-42702-0","volume":"13","author":"EM El-Fakharany","year":"2023","unstructured":"El-Fakharany EM et al (2023) Green synthesis, characterization, anti-SARS-CoV-2 entry, and replication of lactoferrin-coated zinc nanoparticles with halting lung fibrosis induced in adult male albino rats. Sci Rep 13(1):15921","journal-title":"Sci Rep"},{"key":"11237_CR57","unstructured":"W\u0119glarz-Tomczak E et al (2020) Ebselen as a highly active inhibitor of PLProCoV2. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2020.05.17.100768v1#"},{"key":"11237_CR58","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/DDDT.S344750","volume":"16","author":"AE Abdallah","year":"2023","unstructured":"Abdallah AE et al (2023) New series of VEGFR-2 inhibitors and apoptosis enhancers: design, synthesis and biological evaluation. Drug Des Devel Ther 16:587\u2013606","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"11237_CR59","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/14756366.2021.2017911","volume":"37","author":"AE Abdallah","year":"2022","unstructured":"Abdallah AE et al (2022) Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors. J Enzyme Inhib Med Chem 37(1):573\u2013591","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"10","key":"11237_CR60","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.3390\/pharmaceutics13101595","volume":"13","author":"AI Abd-Elhamid","year":"2021","unstructured":"Abd-Elhamid AI et al (2021) Novel nanocombinations of l-tryptophan and l-cysteine: preparation, characterization, and their applications for antimicrobial and anticancer activities. Pharmaceutics 13(10):1595","journal-title":"Pharmaceutics"},{"issue":"1","key":"11237_CR61","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1038\/s41598-022-07456-1","volume":"12","author":"NT Dawoud","year":"2022","unstructured":"Dawoud NT et al (2022) Synthesis, and docking studies of novel heterocycles incorporating the indazolylthiazole moiety as antimicrobial and anticancer agents. Sci Rep 12(1):3424","journal-title":"Sci Rep"},{"issue":"2","key":"11237_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21608\/ajps.2021.187700","volume":"64","author":"M El-Zahabi","year":"2021","unstructured":"El-Zahabi M (2021) Design, molecular modeling and synthesis of new immunomodulatory agents for biological studies. Al-Azhar J Pharm Sci 64(2):1\u201320","journal-title":"Al-Azhar J Pharm Sci"},{"issue":"2","key":"11237_CR63","doi-asserted-by":"publisher","first-page":"185","DOI":"10.21608\/ajps.2012.7145","volume":"46","author":"M Ibrahim","year":"2012","unstructured":"Ibrahim M (2012) Design, synthesis, molecular docking and biological evaluation of some novel quinazolin-4 (3h)-one derivatives as anti-inflammatory agents. Al-Azhar J Pharm Sci 46(2):185\u2013203","journal-title":"Al-Azhar J Pharm Sci"},{"issue":"1","key":"11237_CR64","doi-asserted-by":"publisher","first-page":"12","DOI":"10.21608\/ajps.2020.86011","volume":"61","author":"F Sherbiny","year":"2020","unstructured":"Sherbiny F (2020) Design, synthesis, molecular docking and anti-proliferative evaluation of novel pyrazolo [4, 3-E][1, 2, 4] triazolo [4, 3-C] pyrimidine derivatives as potential DNA intercalators and topoisomerase II inhibitors. Al-Azhar J Pharm Sci 61(1):12\u201328","journal-title":"Al-Azhar J Pharm Sci"},{"issue":"9","key":"11237_CR65","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.3390\/molecules26092806","volume":"26","author":"MS Alesawy","year":"2021","unstructured":"Alesawy MS et al (2021) In Silico studies of some isoflavonoids as potential candidates against COVID-19 targeting human ACE2 (hACE2) and viral main protease (Mpro). Molecules 26(9):2806","journal-title":"Molecules"},{"issue":"3","key":"11237_CR66","doi-asserted-by":"publisher","first-page":"2000237","DOI":"10.1002\/ardp.202000237","volume":"354","author":"MS Alesawy","year":"2021","unstructured":"Alesawy MS et al (2021) Design and discovery of new 1, 2, 4-triazolo [4, 3-c] quinazolines as potential DNA intercalators and topoisomerase II inhibitors. Arch Pharm 354(3):2000237","journal-title":"Arch Pharm"},{"key":"11237_CR67","doi-asserted-by":"publisher","first-page":"115958","DOI":"10.1016\/j.bmc.2020.115958","volume":"30","author":"K El-Adl","year":"2021","unstructured":"El-Adl K et al (2021) [1, 2, 4] Triazolo [4, 3-c] quinazoline and bis ([1, 2, 4] triazolo)[4, 3-a: 4\u2032, 3\u2032-c] quinazoline derived DNA intercalators: design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies. Bioorg Med Chem 30:115958","journal-title":"Bioorg Med Chem"},{"issue":"7","key":"11237_CR68","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.3390\/molecules27072287","volume":"27","author":"IH Eissa","year":"2022","unstructured":"Eissa IH et al (2022) Ligand and structure-based in silico determination of the most promising SARS-CoV-2 nsp16-nsp10 2\u2032-o-Methyltransferase complex inhibitors among 3009 FDA approved drugs. Molecules 27(7):2287","journal-title":"Molecules"},{"issue":"11","key":"11237_CR69","doi-asserted-by":"publisher","first-page":"2100201","DOI":"10.1002\/ardp.202100201","volume":"354","author":"F Khedr","year":"2021","unstructured":"Khedr F et al (2021) Phthalazine-based VEGFR-2 inhibitors: rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations. Arch Pharm 354(11):2100201","journal-title":"Arch Pharm"},{"issue":"1","key":"11237_CR70","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1080\/14756366.2022.2080205","volume":"37","author":"A Elwan","year":"2022","unstructured":"Elwan A et al (2022) Triazoloquinoxalines-based DNA intercalators-Topo II inhibitors: design, synthesis, docking, ADMET and anti-proliferative evaluations. J Enzyme Inhib Med Chem 37(1):1556\u20131567","journal-title":"J Enzyme Inhib Med Chem"},{"key":"11237_CR71","doi-asserted-by":"publisher","first-page":"140595","DOI":"10.1016\/j.molstruc.2024.140595","volume":"1322","author":"AE Abdallah","year":"2025","unstructured":"Abdallah AE et al (2025) New vatalanib analogs: design, synthesis, in silico study and biological evaluation for anticancer activity. J Mol Struct 1322:140595","journal-title":"J Mol Struct"},{"key":"11237_CR72","doi-asserted-by":"publisher","first-page":"107958","DOI":"10.1016\/j.compbiolchem.2023.107958","volume":"107","author":"H Elkady","year":"2023","unstructured":"Elkady H et al (2023) New thiazolidine-2, 4-diones as effective anti-proliferative and anti-VEGFR-2 agents: design, synthesis, in vitro, docking, MD simulations, DFT, ADMET, and toxicity studies. Comput Biol Chem 107:107958","journal-title":"Comput Biol Chem"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11237-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11237-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11237-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T17:03:12Z","timestamp":1771779792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11237-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["11237"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11237-z","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}